期刊文献+

恶性肿瘤肥胖患者代谢综合征及其组分异常的现况及聚集性分析

Status and aggregation of metabolic syndrome and its components abnormality in obese patients with malignant tumor
下载PDF
导出
摘要 目的:探讨恶性肿瘤肥胖患者代谢综合征(metabolic syndrome,MetS)及其相关组分异常的现况及聚集风险。方法:以2020年01月至2022年06月在四川省人民医院健康管理中心有完整体检信息并曾罹患恶性肿瘤的体检者392例作为研究对象,进一步分为肿瘤肥胖组和非肥胖组,并按照性别、年龄相匹配的方式以1∶4的比例选择无肿瘤疾病史及体检信息完整的1658例健康体检人群作为对照组,采用多因素Logistic回归模型分析肿瘤患者肥胖状态下MetS及其组分聚集风险。结果:肿瘤肥胖患者与非肿瘤肥胖患者的MetS患病率均高于健康对照组(64.3%、57.3%vs 10.1%;χ^(2)=201.829,343.372,P<0.001),而肿瘤非肥胖患者的MetS患病率与健康对照组之间差异无统计学意义(7.8%vs 10.1%;χ^(2)=1.515,P=0.218);肿瘤肥胖患者与非肿瘤肥胖患者高血压、高血糖、血脂紊乱的患病率均高于健康对照组(均P<0.05)。肿瘤肥胖患者与非肿瘤肥胖患者的MetS发病风险增加[aOR(95%CI)分别为:18.320(14.396~23.315)、11.496(9.033~14.630)],且异常组分聚集越多,MetS发病风险越大[肿瘤肥胖组3个组分异常和4个组分异常的aOR(95%CI)分别为:13.545(10.643~17.237)、41.431(32.555~52.724);非肿瘤肥胖组3个组分异常和4个组分异常的aOR(95%CI)分别为:8.117(6.378~10.330)、26.549(20.862~33.787)]。异质性检验结果发现,肿瘤肥胖患者与非肿瘤肥胖患者两组的Met S及其组分聚集风险之间差异无统计学意义(均P>0.05)。结论:肿瘤肥胖患者和非肿瘤肥胖的Met S风险均较非肥胖和健康对照人群明显增加,异常组分聚集越多,Met S的发生风险越高。因此,应当针对肿瘤肥胖患者进行有效的体重管理,从而有效的防控肿瘤幸存者其他伴随慢性疾病的发生风险。 Objective:To investigate the status and aggregation risk of metabolic syndrome(MetS)and its related components abnormality in obese patients with malignant tumors.Methods:392 physical examinees who had complete physical examination information and had suffered from malignant tumors in the health management center of Sichuan Provincial People's Hospital from January 2020 to June 2022 were taken as the research objects.They were further divided into tumor obesity group and non obesity group.1658 healthy people without tumor disease history and complete physical examination information were selected as the control group in a ratio of 1∶4 based on gender and age matching.The risk of MetS and its components aggregation in obese tumor patients was analyzed by multivariate Logistic regression model.Results:The prevalence of MetS in tumor obese patients and non tumor obese patients was higher than that in healthy controls(64.3%,57.3%vs 10.1%,χ^(2)=201.829,343.372,P<0.001),but there was no significant difference in the prevalence of MetS between tumor non obese patients and healthy controls(7.8%vs 10.1%,χ^(2)=1.515,P=0.218).The prevalence of hypertension,hyperglycemia and dyslipidemia in tumor obese patients and non tumor obese patients was higher than those in healthy control group(all P<0.05).The incidence risk of MetS increased in tumor obese patients and non tumor obese patients[aOR(95%CI)were 18.320(14.396~23.315)and 11.496(9.033~14.630)respectively],and the more abnormal components gathered,the greater the incidence risk of MetS[aOR(95%CI)of abnormal three components and abnormal four components in obese tumor patients were 13.545(10.643~17.237)and 41.431(32.555~52.724)respectively.The aOR(95%CI)of abnormal 3 and 4 components in non tumor obesity group were 8.117(6.378~10.330)and 26.549(20.862~33.787),respectively].The results of heterogeneity test showed that there was no significant difference in MetS and its component aggregation risk between tumor obese patients and non tumor obese patients(all P>0.05).Conclusion:The risk of MetS in tumor obese patients and non tumor obese patients was significantly higher than that in non obese and healthy controls.The more abnormal components gathered,the higher the risk of MetS.Therefore,effective weight management should be carried out for tumor obese patients,so as to effectively prevent and control the risk of other chronic diseases of tumor survivors.
作者 黄薇羚 张美 郑霄霞 童露瑶 雷理仪 HUANG Weiling;ZHANG Mei;ZHENG Xiaoxia;TONG Luyao;LEI Liyi(Health Management Center,Sichuan Provincial People's Hospital,Affiliated Hospital of University of Electronic Science and Technology of China,Sichuan Chengdu 610072,China)
出处 《现代肿瘤医学》 CAS 北大核心 2023年第23期4414-4419,共6页 Journal of Modern Oncology
基金 国家重点研发计划(编号:2017YFC0113901) 四川省科技厅重点研发项目(编号:2019YFS0278) 四川省卫计委课题(编号:20PJ107)。
关键词 恶性肿瘤 代谢综合征 横断面研究 LOGISTIC回归模型 malignant tumor metabolic syndrome cross sectional study Logistic regression model
  • 相关文献

参考文献6

二级参考文献44

共引文献3304

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部